Skip to content
AnimalAntidiuretic hormone peptide

Vasopressin (ADH analog)

Antidiuretic hormone for water retention & blood pressure.

Overview

V2 receptor (kidney): aquaporin-2 insertion. V1 receptor (vascular): smooth muscle contraction. Also V1a and V1b for pituitary.

Proposed mechanism

Vasopressin is a cyclic nonapeptide that binds to V2 receptors in kidney collecting ducts, inserting aquaporin-2 channels for water reabsorption; V1 receptors in blood vessels cause vasoconstriction.

What the evidence supports

Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.

Graded Animal

Evidence drawn from in vivo animal models or in vitro systems. Mechanistically informative; translation to humans is unproven.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    Vasopressin in diabetes insipidus

    · DOI:10.4158/EP-2019-0546 · 2020

  2. [2]

    Vasopressin pharmacology

    · DOI:10.1016/j.ejphar.2008.03.014 · 2008

  3. [3]

    Vasopressin in diabetes insipidus (2020)

    · · 0

  4. [4]

    Vasopressin pharmacology (2008)

    · · 0

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.

Related profiles

Adipotide (FTTP)

Animal

Targeted fat-depot destruction via vascular apoptosis

Adipotide (also called FTTP) is an experimental peptidomimetic compound designed to selectively destroy the blood supply to white adipose tissue by targeting prohibitin, a protein highly expressed on the vasculature feeding fat cells. Originally developed at MD Anderson Cancer Center, it demonstrated dramatic fat loss in obese rhesus monkeys without dietary restriction. It remains a research compound with no approved human clinical use.

0 RCT · 0 human · 0 preclinical

fat-loss

ARA290 (Cibinetide)

Human-limited

Tissue-protective peptide for nerve repair and inflammation

ARA290, also known as Cibinetide, is a synthetic 11-amino acid peptide derived from the helix B surface peptide of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) without stimulating erythropoiesis. It is designed to harness the tissue-protective and anti-inflammatory properties of EPO while avoiding its hematopoietic side effects. Clinically, it has been investigated for neuropathic pain, small fiber neuropathy, and inflammatory conditions such as sarcoidosis.

0 RCT · 0 human · 0 preclinical

Immune

B7-33

Animal

Biased RXFP1 agonist for cardiac fibrosis

B7-33 is a single-chain peptide analog of human relaxin-2, engineered to selectively activate the RXFP1 receptor without triggering the cAMP signaling pathway. It demonstrates potent anti-fibrotic, vasodilatory, and cardioprotective effects in preclinical models. Research primarily focuses on its potential in heart failure, pulmonary arterial hypertension, and organ fibrosis.

0 RCT · 0 human · 0 preclinical

Cardiovascular